Cancer care is undergoing a seismic transformation, thanks to innovations in precision oncology. Guardant Health is at the forefront of this revolution, offering cutting-edge liquid and tissue biopsy solutions through its Guardant Complete portfolio.
These advanced diagnostic tools empower oncologists to make more informed decisions, improve patient outcomes, and bring a new level of precision to cancer treatment.
What is Guardant Complete?
Guardant Complete is a comprehensive suite of diagnostic tests designed to address critical challenges in cancer care. From detecting minimal residual disease (MRD) to guiding personalized treatment plans and monitoring treatment efficacy, Guardant Complete is a powerful ally for oncologists across the cancer care continuum.
This portfolio is anchored by the Guardant360® liquid biopsy, a non-invasive test that evaluates 739 genes to provide a detailed genomic profile. Whether used at the initial diagnosis or during ongoing treatment, Guardant360® delivers actionable insights that can transform how cancer is managed.
How Does It Work?
Traditional tissue biopsies, while effective, can be invasive, time-consuming, and limited in scope. Guardant Health has revolutionized this process with liquid biopsies that analyze circulating tumor DNA (ctDNA) in the bloodstream. These advanced tests are not only faster but also provide a comprehensive view of a patient’s cancer in a less invasive manner.
For instance:
- Guardant360 Response™ assesses changes in ctDNA levels, offering insights into whether a treatment is working. Results are available in as little as nine days, giving clinicians timely information to adjust therapies as needed.
- Guardant360 TissueNext™ complements liquid biopsies by analyzing tissue samples when needed, ensuring a complete picture of the cancer’s genomic profile.
Why Does This Matter?
Cancer is complex, and effective treatment requires a deep understanding of each patient’s unique disease profile. Guardant Complete eliminates guesswork, helping oncologists tailor treatments to target specific mutations or biomarkers. This level of precision not only improves outcomes but also reduces unnecessary treatments and their associated side effects.
Moreover, the ability to monitor treatment response in real time through tools like Guardant360 Response™ empowers patients and doctors to adapt to the cancer’s behavior dynamically. It’s a proactive approach to a traditionally reactive field.
Shaping the Future of Oncology
Guardant Health’s mission is to conquer cancer with data-driven decisions. By integrating innovative diagnostic tools into routine cancer care, Guardant Complete is setting a new standard in oncology.
As precision oncology continues to evolve, Guardant Health’s solutions are helping pave the way for earlier diagnoses, better treatments, and ultimately, improved survival rates. For patients, this means more hope. For clinicians, it means more clarity in the fight against cancer.
